AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|AAPL345.56-1.55 (-0.45%) ▼|ABBV287.93+1.54 (+0.54%) ▲|ABT102.98-0.12 (-0.12%) ▼|ACN244.04+8.88 (+3.77%) ▲|ADBE246.95-1.41 (-0.57%) ▼|AMAT414.42+18.49 (+4.67%) ▲|AMD569.40+9.14 (+1.63%) ▲|AMGN450.80+2.85 (+0.64%) ▲|AMT181.00-2.83 (-1.54%) ▼|AMZN252.19-0.91 (-0.36%) ▼|AVGO347.69+5.36 (+1.57%) ▲|AXP316.37+3.46 (+1.10%) ▲|BA166.64-1.54 (-0.92%) ▼|BAC50.89+0.21 (+0.41%) ▲|BKNG147.09-3.06 (-2.03%) ▼|BLK1,151.49+15.44 (+1.36%) ▲|BMY60.68-0.87 (-1.41%) ▼|BNY148.30+0.72 (+0.49%) ▲|BRK-B543.91+0.92 (+0.17%) ▲|C123.83+1.14 (+0.93%) ▲|CAT714.36+1.05 (+0.15%) ▲|CL91.56-0.61 (-0.66%) ▼|CMCSA21.67-0.18 (-0.80%) ▼|COF203.88+0.44 (+0.22%) ▲|COP149.96+2.00 (+1.35%) ▲|COST985.89-6.25 (-0.63%) ▼|CRM241.26+0.37 (+0.15%) ▲|CSCO109.94-1.45 (-1.30%) ▼|CVS90.24-0.89 (-0.98%) ▼|CVX231.21+2.98 (+1.31%) ▲|DE639.39-0.19 (-0.03%) ▼|DHR235.51+3.51 (+1.51%) ▲|DIS109.24-0.99 (-0.90%) ▼|DUK123.99-0.82 (-0.65%) ▼|EMR167.23+0.96 (+0.57%) ▲|FDX301.82-5.28 (-1.72%) ▼|GD354.55-0.34 (-0.10%) ▼|GE302.34+4.68 (+1.57%) ▲|GEV883.79-11.29 (-1.26%) ▼|GILD159.55+0.47 (+0.30%) ▲|GM81.30+0.76 (+0.94%) ▲|GOOG320.27+3.44 (+1.09%) ▲|GOOGL323.21+2.63 (+0.82%) ▲|GS921.54+9.77 (+1.07%) ▲|HD318.15-0.35 (-0.11%) ▼|HON219.63+0.82 (+0.37%) ▲|IBM251.93+1.68 (+0.67%) ▲|INTC94.37+0.63 (+0.67%) ▲|INTU328.74+0.29 (+0.09%) ▲|ISRG448.48+2.60 (+0.58%) ▲|JNJ271.63+2.90 (+1.08%) ▲|JPM339.54+3.75 (+1.12%) ▲|KO91.71+0.53 (+0.58%) ▲|LIN508.71+0.06 (+0.01%) ▲|LLY1,289.07+7.16 (+0.56%) ▲|LMT630.70+7.71 (+1.24%) ▲|LOW198.61+0.43 (+0.22%) ▲|LRCX253.16+12.31 (+5.11%) ▲|MA613.22+3.37 (+0.55%) ▲|MCD251.05+1.58 (+0.63%) ▲|MDLZ61.82-0.54 (-0.86%) ▼|MDT95.26+1.31 (+1.39%) ▲|META610.12-10.07 (-1.62%) ▼|MMM172.64+1.06 (+0.62%) ▲|MO73.21-0.28 (-0.38%) ▼|MRK140.47-1.35 (-0.95%) ▼|MS189.53+2.62 (+1.40%) ▲|MSFT526.45-4.88 (-0.92%) ▼|MU967.73+38.97 (+4.20%) ▲|NEE81.23-1.20 (-1.45%) ▼|NFLX61.60-0.93 (-1.48%) ▼|NKE37.24-0.33 (-0.87%) ▼|NOW149.79-5.00 (-3.23%) ▼|NVDA216.57-1.37 (-0.63%) ▼|ORCL129.61-0.93 (-0.71%) ▼|PEP132.65-0.85 (-0.64%) ▼|PFE29.31-0.49 (-1.64%) ▼|PG158.93-0.31 (-0.19%) ▼|PLTR193.43-5.31 (-2.67%) ▼|PM203.24+0.62 (+0.31%) ▲|QCOM180.64-3.53 (-1.92%) ▼|RTX197.45+2.85 (+1.46%) ▲|SBUX104.04+1.00 (+0.97%) ▲|SCHW88.30-1.00 (-1.12%) ▼|SO91.82-0.84 (-0.90%) ▼|SPG211.73-0.55 (-0.26%) ▼|T20.67-0.28 (-1.31%) ▼|TMO707.71+14.69 (+2.12%) ▲|TMUS145.50-1.33 (-0.91%) ▼|TSLA401.93-5.54 (-1.36%) ▼|TXN307.07-1.84 (-0.60%) ▼|UBER65.17-0.61 (-0.92%) ▼|UNH408.29-2.11 (-0.51%) ▼|UNP299.31-0.57 (-0.19%) ▼|UPS104.32-1.78 (-1.67%) ▼|USB59.35-0.39 (-0.65%) ▼|V402.18+0.32 (+0.08%) ▲|VZ43.19-0.75 (-1.70%) ▼|WFC83.94+1.28 (+1.55%) ▲|WMT119.15-0.18 (-0.15%) ▼|XOM182.72+2.81 (+1.56%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: protein

newsFORsourcecompanycontentinformation1releasesmarket

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the ‘Treat Early’ Strategy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease...

Coffee Island debuts in Delhi with its first ever 24/7 café in GK II

The new café is strategically located to position the brand at the heart of Delhi's high-street coffee culture NEW DELHI, June 6, 2025 /PRNewswire/ --...

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President...

Friedreich’s Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new...

Maple Leaf Foods Releases 2024 Integrated Report Highlighting Sustainability and Strategic Achievements

Purpose-driven consumer packaged goods protein company continues unwavering commitment to sustainability, shared value, and strategic growth MISSISSAUGA, ON, June 5, 2025 /PRNewswire/ - (TSX: MFI)...

Superbrewed Food Announces Clinical Study of Postbiotic Cultured Protein Benefits

NEW CASTLE, Del., June 5, 2025 /PRNewswire/ -- Superbrewed Food, a trailblazer in innovative food ingredients, is proud to announce the presentation of research...

bitBiome Announces Strategic Partnership with Leading CMO for Manufacturing and Supply of Products

TOKYO, June 5, 2025 /PRNewswire/ -- bitBiome, Inc., a biotechnology company unlocking the potential of our planet's microbes to power the future of the...

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain.

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year 
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis

First-in-class agent targets WISP1 in patients with IPF Primary endpoint in WISPer trial is change in Forced Vital Capacity (FVC) at 24 Weeks BOSTON, June 5,...

VitaHustle® Launches at The Vitamin Shoppe® to Bring Clean, All-in-One Nutrition to Consumers Nationwide

Innovative nutrition shake brand, founded by Kevin Hart, is now available in-store and online LOS ANGELES, June 5, 2025 /PRNewswire/ -- VitaHustle, the wellness brand founded...

Global Nutraceutical Products Market Estimated to Reach USD 912.25 Billion by 2030, Growing at a 7.50% CAGR: MarkNtel Advisors

NEW DELHI, June 5, 2025 /PRNewswire/ -- The Global Nutraceutical Product Market size was valued at around USD 591.1 billion in 2024 and is expected...

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells 
Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProtein

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers